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ABSTRACT
Objective: To assess the cost-effectiveness of
erlotinib versus supportive care (placebo) overall and
within a predefined rash subgroup in elderly patients
with advanced non-small-cell lung cancer who are unfit
for chemotherapy and receive only active supportive
care due to their poor performance status or presence
of comorbidities.
Setting: Between 2005 and 2009, a total of 670
patients with non-small cell lung cancer (NSCLC) were
randomised across 78 hospital sites (centres) in
the UK.
Participants: 670 patients with pathologically
confirmed stage IIIb-IV NSCLC, unfit for chemotherapy,
predominantly poor performance status (>2 on Eastern
Cooperative Oncology Group, ECOG) and estimated life
expectancy of at least 8 weeks. Patients were followed
until disease progression or death, including a
subgroup of patients who developed first cycle rash.
Interventions: Patients were randomised (1:1) to
receive best supportive care plus oral placebo or
erlotinib (150 mg/day) until disease progression,
toxicity or death.
Primary outcome: Overall survival (OS).
Secondary outcomes: Progression-free survival
(PFS), tumour response and quality adjusted life
years (QALY), including within prespecified
subgroups.
Results: The mean incremental cost per QALY in all
patients was £202 571/QALY. The probability of cost-
effectiveness of erlotinib in all patients was <10% at
thresholds up to £100 000. However, within the rash
subgroup, the incremental cost/QALY was £56 770/
QALY with a probability of cost-effectiveness of about
80% for cost-effectiveness thresholds between
£50 000 to £60 000.
Conclusions: Erlotinib has about 80% chance of
being cost-effective at thresholds between £50 000–
£60 000 in a subset of elderly poor performance
patients with NSCLC unfit for chemotherapy who
develop first cycle (28 days) rash. Erlotinib is
potentially cost-effective for this population, for which
few treatment options apart from best supportive care
are available.
Trial registration number: (ISCRTN): 77383050.
INTRODUCTION
Lung cancer, the leading cause of cancer-
related death, accounts for nearly 1.4 million
deaths worldwide annually, with a yearly inci-
dence of over 41 000 in the UK,1 2 of which
80% are non-small cell lung cancer
(NSCLC).3 In the USA, the mean monthly
cost of treating patients with lung cancer was
estimated at £1669 (no active treatment,
about £1669; £1=$1.61 US) and £5814 (che-
moradiotherapy).4 In the UK, the total
annual cost of treating lung cancer in 2012
equated to about £2.4 billion5—the yearly
average cost per patient was £9071. This com-
pares with £2756 for bowel cancer, £1584 for
prostate cancer and £1076 for breast cancer.
The costs associated with lung cancer are
therefore a signiﬁcant economic burden on
healthcare systems worldwide.
Strengths and limitations of this study
▪ A randomised controlled trial designed prospect-
ively to assess the cost-effectiveness of erlotinib
in a predefined subgroup. Rash is used as a
retrospective surrogate marker to select patients
to continue erlotinib treatment after 4 weeks trial
of treatment.
▪ Quality of Life Data were obtained prospectively
up to and beyond progression. In most
trials Quality of Life is collected only up to
progression.
▪ More than 99% of patients died, therefore, the
uncertainty in modelling future health benefits is
largely absent in this analysis.
▪ This is an important contribution in an area
where there is limited data on the cost-effective-
ness of cancer treatments in elderly patients.
▪ The potential economic impact of erlotinib use in
the 60% of patients who develop rash is likely to
be significant for the UK National Health Service
(NHS).
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It is estimated about 30% of patients with advanced
NSCLC do not receive any cytotoxic treatment6 because
of poor performance status and/or multiple medical
comorbidities. The National Institute for Health and
Care Excellence (NICE) does not recommend erlotinib
treatment for epidermal growth factor receptor (EGFR)
mutation-negative patients.7 NICE previously recom-
mended erlotinib as an alternative treatment to doce-
taxel for patients with good performance status who
have tried at least one chemotherapy treatment.8 The
current cost-effectiveness thresholds (willingness to pay)
proposed by NICE are £20 000–£30 000 per QALY;
however, for special cases, such as end-of-life treatments,
supplementary guidance was issued, which suggested a
higher threshold to £50 000/QALY.
The recently published TOPICAL trial9 was a rando-
mised (1:1), double blind, phase III multicentre trial con-
ducted in the UK comparing erlotinib (ER) with placebo
in predominantly elderly patients receiving best support-
ive care considered unﬁt for chemotherapy because of
poor performance status and/or multiple medical
comorbidities, including renal impairment. The median
overall survival (OS) was 3.7 versus 3.6 months for erloti-
nib versus placebo; (HR=0.94; 95% CI 0.81 to 1.1;
p value=0.46).9 However, in prespeciﬁed subgroup ana-
lyses in patients who developed rash after about 28 days
(1 cycle), OS improved with erlotinib; (OS HR=0.76; 95%
CI 0.63 to 0.92; p value=0.0058 and progression-free sur-
vival (PFS) HR=0.66; 95% CI 0.54 to 0.80; p value<0.001);
median OS of 2.9 versus 6.2 months.
About 178/302 (60%) of patients in the TOPICAL
trial developed rash with erlotinib in the ﬁrst treatment
cycle and >70% developed rash at any time, consistent
with what has been reported elsewhere.9 In the UK
alone, about 30–40% of patients with NSCLC are unﬁt
for chemotherapy,9 therefore, assuming a worldwide
advanced NSCLC incidence of approximately 1 million,2
the potential economic impact of erlotinib use in the
60% of treated patients who develop rash is likely to be
signiﬁcant. We present the results of a cost-effectiveness
analysis of erlotinib versus placebo overall and within a
predeﬁned subgroup of patients who develop rash
within the ﬁrst (28 days) of treatment. The rationale for
erlotinib treatment beneﬁt in patients who develop rash
has been discussed extensively.9–11
PATIENTS AND METHODS
Patients
The patient population included in this analysis were
newly diagnosed stage IIIb–IV (pathologically con-
ﬁrmed) patients with NSCLC who were chemotherapy
naïve with no symptomatic brain metastases, and deemed
unsuitable for chemotherapy by treating physicians based
on the Eastern Cooperative Oncology Group (ECOG)
performance status (PS ≥2) and/or multiple medical
comorbidities including renal impairment.
Patients were followed up until progression or death.
The primary end point was OS; secondary end points
were PFS, safety and health-related quality of life
(HRQoL). PFS was deﬁned as the time between random-
isation and progression or death (whichever occurred
ﬁrst). Progression was based using the response evalu-
ation criteria in solid tumours (RECIST). Prespeciﬁed
subgroup analyses included whether or not patients
developed treatment-related rash within the ﬁrst 28 days
(ﬁrst-cycle rash), gender and histology. HRQoL using
EuroQoL EQ-5D-3L (EQ-5D) was assessed monthly.
Randomised patients who took study medication were
included in this analysis. Rash was assessed using a sub-
jective 5 point scale graded from: no rash (grade 0), ery-
thema alone (grade A), erythema with papules (grade
B), erythema with papules and pustules (grade C) and
erythema with papules and conﬂuent pustules (grade D).
Rash is a common side effect of erlotinib. In this analysis
we included patients with all rash grades, regardless of
expected relationship with study treatment. Patients con-
sidered to have an outcome of rash were those recorded
to have a rash score of A–D. Those with a grade 0 were
considered to have no rash.
Treatments
The main comparison is patients randomised to erloti-
nib who developed ﬁrst cycle rash (ER) versus placebo.
All patients were allowed to receive immediate or
delayed palliative chest radiotherapy and/or radiother-
apy to metastatic sites as appropriate.
Patients received erlotinib (150 mg) or matching
placebo daily until progression. Dose reductions to
100 mg or 50 mg were allowed. Patients who took erloti-
nib but did not develop rash (ENR) are discussed in the
sensitivity analyses.
Costs/resources
The costs relevant for this analysis were costs from drug
(erlotinib), radiotherapy, additional anticancer treat-
ments (eg, other tyrosine-kinase inhibitor (TKI) or
mono chemotherapy), patient management (hospital
clinic visits, day cases and hospital admissions) and man-
aging important treatment related-adverse events (AEs;
eg, diarrhoea and rash). Resource use was collected
monthly on the case report forms (CRF). Unit prices
were taken from hospital pharmacy records, published
NICE reports7 8 12 (where available), published litera-
ture,13 14–16 National Health Service (NHS) reference
costs17 and the British National Formulary (BNF,
2012),18 without adjusting for inﬂation. Costs were esti-
mated in UK (£) sterling. No discounting was applied to
costs or health beneﬁts <1 year; discounting at 3.5% per
annum was applied in the second year; nearly all
patients (>99%) progressed/died by 2 years.
Drug use
Erlotinib price was set at £54.37/tablet for 150 mg,
£44.12 for 100 mg and £25.21 for 50 mg.7 8 Drug use was
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determined from the recorded number of tablets dis-
pensed and returned. Drug cost per patient was estimat-
ing by multiplying the duration of erlotinib use by the
unit price. For placebo, drug cost was set to zero. Where
additional treatments were given (for palliation), unit
costs were identiﬁed.
Supportive care
The mean price of palliative radiotherapy (including
planning) for advanced stage patients with NSCLC was
assumed to be £120 per visit using NHS reference prices
(2011–2012).17 The total radiotherapy cost is computed
by multiplying the duration of therapy by the unit price.
Costs for additional anticancer treatments were included
in the analysis; the daily price of gemcitabine/carbopla-
tin was assumed to be £47.50; for vinorelbine it was
£19.18.14 15
Clinic visits/admissions
Resource use (hospital and additional clinic visits, day
cases, night hospital stays) were recorded on the CRFs.
Only hospitalisations from AEs that were recorded as
deﬁnitely/probably/possibly treatment related were
used to compute costs of hospital overnight stays. The
price/day for a clinic visit was £100; day case was £670
and an additional £730 for overnight stay (ie, £1400
including admission).17
Adverse events
Clinically important grade 3 and above serious adverse
events (SAEs) with >5% frequency were: rash, diarrhoea
and dyspnoea;9 other toxicity rates (≤1%) were similar
between treatments and expected cost differences were
negligible. Patients with any grade (maximum AE grade)
were included; it was assumed that palliative treatment
was taken, even if AEs were milder. For rash and diar-
rhoea, the costs per day were set to £4.30 and £8.59,
respectively;16 the cost of morphine at 15 mL/day is
about £0.22; steroid use (dexamethasone) based on
£13.80 per 100 tablets with standard doses of 3 tablets of
4–8 mg per day was set at £0.42/daily dose; with salbuta-
mol assuming £0.13/daily dose.18
Duration of AEs was computed from their start/end
dates; daily unit prices of medications for treating AEs
(following UK practice) were computed based on a
monthly course.18 The total cost (per patient) was com-
puted by adding component costs: drug cost, supportive
care, palliative radiotherapy (RT), additional clinic visits,
hospital day cases, hospital admissions and treatments
for SAEs.
Utilities
The EQ-5D was used to construct health utilities for
economic evaluation. The EQ-5D consists of 5 scales
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression) collected from baseline until pro-
gression/death. Responses were converted into utilities
using a UK social tariff based on the time trade off
method.19 Missing utility data were handled through mul-
tiple imputation (MI) techniques. Responses to EQ-5D
were captured on paper CRFs during clinic assessments
(monthly in year 1 and 6 monthly thereafter).
Cost-effectiveness analysis
A patient level (Partitioned Survival) cost utility analysis
was undertaken. The OS, PFS and post-progression sur-
vival (PPS) were determined for each patient. Mean
EQ-5D utilities over time were estimated for pre and
postprogression periods and multiplied by correspond-
ing survival times to derive QALYs for each patient. The
total costs were then modelled to derive mean costs.
Finally, mean incremental costs, QALYs and the incre-
mental cost-effectiveness ratio (ICER) were derived.
Sensitivity analysis
One way sensitivity analyses were carried out, varying
resource use by ±20%. In addition, a probabilistic sensi-
tivity analysis (PSA) was carried out using Monte-Carlo
simulation (10 000 simulations) using multivariate
methods.20
For each data set simulated, the incremental net
beneﬁt (INB) was computed using the relationship:
INB=λ*ΔE–ΔC, where λ is the CE threshold, ΔE, the
mean incremental effect and ΔC the mean incremental
cost. The proportion of INBs above or below varying
values of λ (ranging from £1000 to £100 000) was used
to approximate the probability of cost-effectiveness.
Statistical analysis
A patient level statistical modelling approach was used to
determine mean incremental costs and effects. Mean
OS and PFS were determined using Kaplan-Meier
methods. Utilities were modelled using linear mixed
effects models for repeated measures adjusting for base-
line and for whether the observed utility occurred pre-
progression or postprogression. Mean incremental
QALYs were subsequently derived. No extrapolation of
OS and PFS was carried out (>99% of patients had died
at the time of analysis).
Total costs were modelled using a generalised linear
model assuming a gamma distribution to derive the
incremental mean costs.21 Since costs are positive (>0)
and skewed, a gamma distribution was considered to be
adequate,21 22 although this requires a small increment
of 0.001 to be added if costs are zero for modelling pur-
poses. MI methods with a maximum of three data sets
were used for missing data. The resulting SEs from MI
were used to revise estimates of the ICER in sensitivity
analyses. Simulation of cost and effects for PSA was
carried out using multivariate methods23 by generating
data from a Normal Copula.24 All analyses were con-
ducted using SAS V.9.3.
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RESULTS
Baseline characteristics
Between 2005 and 2009, a total of 670 (350 erlotinib;
320 placebo) patients were randomised across 78 centres
in the UK. From 334 versus 313 patients who took study
treatment, a prespeciﬁed subgroup of 302 erlotinib
versus 278 placebo was evaluable for ﬁrst cycle rash
(ﬁgure 1 CONSORT). The main comparison of interest
in this CE analysis is the subgroup ER (n=178) versus
placebo (n=278), since overall there were no differences
between erlotinib and placebo; 178/302 (59%) devel-
oped rash in the ﬁrst cycle (ER group) and 124/302
(41%) took erlotinib and did not develop rash in the
ﬁrst cycle (Erlotinib non-rash (ENR) group); 5/313
(2%) on placebo had rash. Patients with ENR were
included in a sensitivity analysis. Baseline characteristics
were generally similar between groups (table 1).
Although there appeared to be a difference for smoking
status (except never-smokers), a multivariate analysis9
showed that overall survival was similar between
ex-smokers and never-smokers (HR 0.98). Also, the
efﬁcacy of erlotinib may be reduced in patients who cur-
rently smoke, but the absolute difference of 24% versus
37% (p=0.003) does not materially impact the estimate
of the QALY and ICER; and, furthermore, we have
shown that efﬁcacy is improved in the erlotinib-rash
group.
Costs/resources
Erlotinib was taken as 150 mg tablets by about 83% of
patients, without any dose reductions; 15% and 2% of
patients reduced dose to 100 mg and 50 mg, respectively.
In the rash subgroup this was 79% for 150 mg tablets,
20% for 100 mg and 1% for 50 mg tablets, respectively.
Hence, after taking into account dose reductions and
dose delays, the mean cost of erlotinib (table 2) was
£6863 overall and £7544 in the rash subgroup. For ER
versus placebo, additional chemotherapy/TKI costs after
progression on the erlotinib arm (n=7) and placebo
group (n=5) were £182 versus £270, respectively (mean
difference £88, p value=0.852); mean costs for palliative
radiotherapy were £302 versus £235 (p value=0.0449);
Figure 1 Consort diagram.
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mean duration of radiotherapy was longer with erlotinib
(2.5 vs 2.0 days; p value=0.3412), although the propor-
tion of patients who received radiotherapy was similar
(table 2 and online supplementary table S1). More
patients were hospitalised for treatment-related SAEs on
ENR versus placebo: 22/178 (12%) versus 15/278 (5%);
mean costs of treatment related SAEs were, therefore,
£356 versus £184 and mean total costs were £9949 versus
£2058, respectively.
Efficacy
The mean and SE for OS was 7.08 (0.48) versus 6.41
(0.44) months. For PFS, this was 4.95 (0.36) versus 3.80
(0.29) months, respectively (erlotinib vs placebo). In the
rash subgroup, OS was 9.08 (0.65) versus 6.91 (0.43)
months (table 2); and PFS was 6.22 (0.51) versus 4.19
(0.32) months for ER and placebo, respectively.
Utilities and QALYs
About 98% of EQ-5D forms were completed at baseline;
patients alive at 1 year, 32/40 (80%) versus 34/43 (79%)
had complete EQ-5D data for ER versus placebo, respect-
ively. Missing data between groups were similar at other
time points. As expected, HRQoL was better before pro-
gression (table 1): pre-progression utility was 0.6482
(0.009) versus 0.6438 (0.011); for postprogression, mean
(SE) utilities were 0.5517 (0.016) versus 0.5760 (0.0140)
for erlotinib versus placebo, respectively. In the rash sub-
group, EQ-5D utility improvement was higher prior to
disease progression: 0.6407 (0.017) versus 0.6193 (0.015);
mean difference was 0.0214 (95% CI, -0.0122, 0.0651;
p value=0.3408); for post-progression, mean (SE) was
0.5548 (0.0255) versus 0.5756 (0.0200); mean difference
of -0.0243 (95% CI, −0.0084, 0.0429; p value=0.5229) for
ER versus placebo, respectively.
The mean QALY was 0.365 versus 0.3303 overall, yield-
ing an incremental QALY of 0.035. In the rash subgroup,
the mean QALY was, respectively, 0.467 versus 0.337 for
ER versus placebo, yielding a statistically signiﬁcant
mean incremental QALY of 0.139 (95% CI 0.0341 to
0.2359; p value=0.0070), in favour of erlotinib. The
improved QALY within the rash subgroup appears to be
due to improved survival (table 3), notably PFS. Hence,
the mean incremental cost was £7090 and an overall
ICER of £202 571/QALY.
In the rash subgroup, the mean incremental cost was
£7891 (95% CI £6999–£8783), but with better HRQoL/
utility resulting with a base case ICER of £56 770/QALY
(table 4). The incremental cost excluding erlotinib cost
was £347 and the ICER was £2496/QALY in the rash sub-
group. The mean incremental net beneﬁt (INB) for
erlotinib is not realised until one is prepared to pay in
excess of about £202 571 overall and £56 770 in the rash
subgroup.
Assessing uncertainty
Sensitivity analyses were conducted for the rash sub-
group only. However, as part of the sensitivity analyses,
the impact on the ICER was observed from patients in
the ENR group who took erlotinib—since these patients
would contribute towards the costs of erlotinib in prac-
tice,for at least one cycle.
Results from one way sensitivity analyses are shown in
table 4. The ICER was most sensitive to changes (±20%) in
Table 1 Summary of baseline characteristics*
Overall Rash subgroup
Erlotinib (N=350) Placebo (N=320) p Value Erlotinib (N=178) Placebo (N=278) p Value
Age
Median 77 78 0.899 78 78 0.991
Range (45–91) (51–91) (51–91) (45–91)
Gender
Female 135 (39%) 126 (39%) 0.833 69 (39%) 108 (39%) 0.984
Male 215 (61%) 194 (61%) 0.834 109 (61%) 170 (61%) 0.983
ECOG
0–1 54 (15%) 53 (16%) 0.692 37 (21%) 50 (18%) 0.459
2 194 (55%) 185 (56%) 0.539 103 (58%) 165 (59%) 0.756
3 102 (25%) 90 (27%) 0.771 38 (21%) 63 (23%) 0.741
Cell type
Adenocarcinoma 133 (38%) 123 (38%) 0.908 63 (35%) 103 (37%) 0.718
Large cell 15 (4%) 15 (5%) 0.801 7 (4%) 15 (5%) 0.477
Squamous 136 (39%) 127 (40%) 0.825 75 (42%) 114 (41%) 0.810
Other NSCLC 66 (19%) 55 (17%) 0.574 33 (19%) 46 (17%) 0.582
Smoking status
Smoker 124 (35%) 119 (37%) 0.631 43 (24%) 104 (37%) 0.003
Ex-smoker 207 (59%) 183 (57%) 0.608 122 (69%) 158 (57%) 0.012
Never smoked 19 (5%) 18 (6%) 0.911 13 (7%) 16 (6%) 0.509
*Only those patients who took study drug were included in the analysis.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
Khan I, et al. BMJ Open 2015;5:e006733. doi:10.1136/bmjopen-2014-006733 5
Open Access
Table 2 Model inputs: unit prices for resource use and summary of costs
Costs Item
Estimated
unit price (£)
Rash subgroup Overall (£)
Erlotinib (rash) (£) Placebo/SC (£)
Difference
(p value) (£)
Erlotinib Placebo/SC
Difference
N=178
Mean (SE)
N=278
Mean (SE)
N=334
Mean (SE)
N=313
Mean (SE)
Erlotinib* 54.37/tablet 7544 (764) 0 7544 6863 (674) 0 8074
Supportive care:
Palliative RT† 120/visit 302 (52) 235 (27) 67 (p=0.0449) 350 (48) 242 (39) 108
Additional treatment‡ See note c 182 (65) 270 (99) −88 (p=0.85) 190 (59) 264 (76) −74
Patient management:
Hospital clinic visit§ 100/visit 629 (57) 624 (53) 5 (p=0.46) 663 (49) 654 (40) 9
Hospital day case§ 670/day case 274 (65) 323 (131) −49 (p=0.69) 285 (71) 356 (95) −71
Hospital admission§ 730/night 744 (163) 475 (134) 269 (p=0.0352) 775 (149) 534 (122) 241
Adverse events¶ See note e 221 (34) 114 (27) 107 (p<0.001) 264 (40) 181 (32) 83
Total mean cost (SE)**
(95% CI)
9949 (724)
(8530 to 11 368 )
2058 (185)
(1695 to 2420)
7891 p<0.001) 9210 (711) 2121 (199) 7089
Incremental Cost (SE)** 7891 (614) (95% CI 6999 to 8783) 7089 (589) (95% CI £5935 to £8243)
*Cost as £1631.53 for 30 tablets (150 mg tablet) or depending on dose; +Unit price based on national NHS tariff (NICE report 2011).7 9
†Palliative RT: Diagnosis and treatment of lung cancer update (2011).9
‡On the Placebo arm, 7 patients took additional chemotherapy (carboplatin/gemcitabine (n=5) erlotinib (n=2)) after progression; on the erlotinib arm, patients took carboplatin (n=2), vinorelbine
(n=2), Fragmin (n=1).11 12
§Additional clinic visits and day visits irrespective of reason; unit prices taken from NHS reference costs 2010–2011; Hospital nights stayed as a result of treatment-related serious adverse
events.13
¶Total costs for diarrhoea, rash and dyspnoea; duration of each AE was computed from the date of onset of the event to date resolved. Rash unit price taken from Lewis et al 201014; morphine
dose of 15 mL/daily is about £0.22/day; steroid use (dexamethasone) based on £13.84 per 100 tablets and taking 3 tablets of 4–8 mg per day gives £0.42/daily dose; inhaler: salbutamol, £0.13/
daily dose.15 Mean diarrhoea costs were £14 versus £2; mean rash costs were £68 versus £14.90 and mean dyspnoea costs were £139 versus £97.
**Determined using a generalised linear mixed model assuming gamma distributed costs for Erlotinib+Rash versus Placebo.NHS, National Health Service; NICE, National Institute for Health
and Care Excellence; RT, radiotherapy.
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erlotinib costs, and utilities ranged from £45 821/QALY to
£67 530/QALY. Most ICERs remained within 5% of the
base case after ±20% adjustments. The mean ICER from
PSA was £57 120 with 5% and 95% quantiles ranging from
£29 438 to £89 550. The estimated probability of cost-
effectiveness of erlotinib at CE thresholds between £50 000
to £60 000 was 80% (ﬁgure 2A). The CE plane (ﬁgure
2B) shows costs and beneﬁts scattered in the north east
quadrant where incremental effects are generally positive
(erlotinib better), but with higher costs.
Patients who started erlotinib but did not develop rash
after the ﬁrst cycle (ENR) are considered to contribute
towards drug costs during the ﬁrst cycle. Patients with
ENR who took erlotinib for at least one cycle had worse
outcomes: OS and PFS HRs of 1.30 and 1.09 compared
to placebo, with mean (SE) OS and PFS of 5.7 (0.69)
and 4.2 (0.55) months, respectively.9 These patients are
unlikely to continue erlotinib if rash is not observed
within the ﬁrst cycle (but may continue to receive SC).
The mean cost of 28 days of erlotinib after accounting
for dose delays and reductions was £1279. The total
mean erlotinib cost was, therefore, £8187. Hence, after
adjusting for all other costs (AEs, supportive care includ-
ing RT, hospital visits) during the PFS period, the incre-
mental cost and ICER increased to £9578 and £68 906,
respectively, assuming an incremental QALY of 0.139.
The base case ICER was robust to differences in the
models and methods of handling missing utility data.
When MI was used, the ICER did not increase (table 4)
beyond £58 400 (range £55 452 to £58 400). The SEs of
incremental costs and QALYs increased slightly from
£614 to £689 and 0.0113 to 0.0145, respectively, after
taking into account missing data, using MI. A summary
of ICER results are shown in table 5.
DISCUSSION
In this trial in a population of patients with advanced
NSCLC considered unﬁt for ﬁrst-line chemotherapy,
erlotinib did not show cost-effectiveness overall, however,
it has potential for being cost-effective in patients who
develop ﬁrst cycle rash. At the time of our original
report,9 previous phase III NSCLC clinical trials sug-
gested a relationship between rash development and
improved survival with TKI treatment.10 25 26 This has
since been conﬁrmed in a meta-analysis of 33 trials
(6798 patients) of NSCLC, from which the authors con-
cluded that skin rash after EGFR-TKI treatment is an
effective surrogate marker for predicting clinical out-
comes.11 Our ﬁndings are also consistent with several
other studies to report the relationship between TKIs/
EGFR antibodies and rash in different cancer types:
Bonner, 2010 (head and neck cancer),27 Cunningham
(2004) and Bokemeyer (2009)28 in colorectal cancer.29
The monthly cost of erlotinib treatment was £16509
and at least £911215 for six cycles. This trial demon-
strated effects in our patients for whom few treatment
Table 3 Model inputs: effectiveness measures
Overall Rash subgroup
Erlotinib (N=334) Placebo (N=313) Erlotinib (N=178) Placebo (N=278)
Mean OS (months) 7.08 (0.48) 6.41 (0.44) 9.08 (0.65) 6.91 (0.43)
Mean PFS (months) 4.95 (0.36) 3.80 (0.29) 6.22 (0.51) 4.19 (0.32)
Mean PPS (months) 2.13 (0.250) 2.61 (0.236) 2.86 (0.41) 2.72 (0.27)
HR (OS) 0.92 0.76
(95% CI; p value) (0.79 to 1.08; p value=0.32) (0.63 to 0.92; p value=0.005)
HR (PFS) 0.81 0.66
(95% CI; p value) (0.70 to 0.95; p value=0.0102) (0.54 to 0.80; p value<0.0001)
Utilities
Preprogression EQ-5D (mean, SE) 0.6482 (0.009) 0.6438 (0.011) 0.6407 (0.017) 0.6193 (0.015)
Postprogression EQ-5D (mean, SE) 0.5517 (0.016) 0.5760 (0.014) 0.5548 (0.0255) 0.5756 (0.020)
QALY (years)* 0.365 (0.0272) 0.3303 (0.0245) 0.487 (0.0432) 0.3472 (0.0260)†
Incremental QALY (mean SE)‡ 0.035 (0.0163) 0.139 (0.0113)
*This is computed as (preprogression utility)×PFS+(postprogression utility)×PPS.
†Statistically different between erlotinib and placebo (p value: 0.0070).
‡Erlotinib versus placebo.
PFS, progression-free survival; PPS, postprogression survival; OS, overall survival.
Table 4 One way sensitivity analysis (rash subgroup)
Parameter Variation (%) ICER (£)
Base case 56 768
Erlotinib cost −20 45 821
+20 67 530
Radiotherapy costs −20 56 823
+20 55 953
Hospital admission costs −20 54 018
+20 58 758
Preprogression utility −20 97 671
+20 48 945
Postprogression utility −20 160 019
+20 49 845
Missing data adjustments* – <58 400
*Using multiple imputation.
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options are available apart from palliative radiotherapy.
OS improved by a median of >3 months9; Improvements
in HRQoL were also demonstrated with the
EORTC-QLQC-30.9 Consequently, ER patients show a
high probability (about 80%) of being cost-effective at
thresholds between £50 000 and £60 000; this threshold
is advocated by supplementary NICE guidelines (in the
UK) for end of life treatments.30 Moreover, at lower CE
thresholds (eg, £30 000–£40 000), between 15% to 40%
(ﬁgure 2A) of our patients with NSCLC unﬁt for chemo-
therapy would have a cost-effective clinical beneﬁt (ie,
>3 months improvement in OS and improved HRQoL).
With few treatment options available for these patients,
this is an important ﬁnding.
From published trials, the cost/QALY of erlotinib
ranges from £18 170 to £89 377 (incremental QALYs
Figure 2 Cost-effectiveness
results. (A) Cost-Effectiveness
Acceptability Curve (CEAC): ER
versus Placebo/SC for rash
subgroup. Note: Vertical
reference lines are CE threshold
values of £50 000 and the
observed cost/QALY (£56 770).
The horizontal reference line is
0.8. (B) Cost-Effectiveness Plane:
ER versus Placebo/SC (rash
subgroup). Note: The first vertical
reference line is 0. The horizontal
and second vertical reference
lines are observed incremental
effect (0.139) and observed
incremental cost (£7891),
respectively.
Table 5 Summary of results from Cost Utility Analysis (CUA)
Scenario Incremental costs Incremental effects ICER (5th, 95th centile)
Overall (base case)† £7090 0.139 £202 571
Rash subgroup
Base case‡ £7891 0.139 £56 770 (£29 438 –£89 550 )
Excluding erlotinib costs £347 0.139 £2496 (£1120–£3895)
Including ENR 1st cycle drug costs§ £9578 0.139 £68 906 (£44 165–£93 276 )
†Erlotinib versus placebo (n=647).
‡ER versus placebo (n=456).
§ER (including ENR first cycle erlotinib costs) versus placebo.
ENR, Erlotinib non-rash; ICER, incremental cost-effectiveness ratio.
8 Khan I, et al. BMJ Open 2015;5:e006733. doi:10.1136/bmjopen-2014-006733
Open Access
ranging from 0.175 to 1.4).16 31–38 The observed QALY
of 0.139 in ER patients was within this range. Reported
ICERs in EGFR mutation +ve patients for other TKI
therapies include: afatinib (ICERs between $45 000
(£23 000) to $75 000 (£38 600)/QALY when compared
with geﬁtinib, erlotinib and cisplatin/gemcitabine)39 for
geﬁtinib £21 000 (vs gemcitiabine) to £154 000/QALY
(vs cisplatin/gemicitabine).40 However, these were in
trials where patients were ﬁt for standard chemotherapy.
Non-TKI’s such as pemetrexed reported ICERs between
£18 672 (vs BSC)41 to £49 000/QALY (vs BSC).42
Crizotinib: ICERs ranging from about £41 500/QALY43
versus docetaxel to $216 000/QALY when compared
with pemetrexed.44
In a recent review of licenced treatments for NSCLC,
it was highlighted that the elderly frail population were
unrepresented in the majority of lung cancer trials and
there remains considerable uncertainty in assessing the
cost-effectiveness of treatments for this group of
patients.45 Moreover, many of these trials did not report
the cost/QALY, which would be helpful to decision-
makers. Interestingly, in a phase II erlotinib trial that did
include elderly patients (ﬁt for chemotherapy), the
reported ICER was €395 400 (£341 198/QALY).46
In the UK, the NICE supplementary guidance recog-
nises that during end of life, the standard CE thresholds of
£20 000–£30 000 per QALY gain may be inadequate.31 47
Two of these three criteria (short life expectancy and
≥3 months improvement in survival) were satisﬁed. The
third criteria: ‘treatment is licensed or otherwise indicated
for small patient populations’ is not clearly satisﬁed; poor
performance patients with NSCLC is not considered to be
a ‘small’ patient population, despite this population being
understudied.45 A ‘small population’ should not normally
‘exceed 7000 new patients per year’ or should be a ‘small
group within larger populations’.31
There are several strengths in our analyses. First, the
TOPICAL trial was designed to prospectively record
health economic data (eg, collecting resource use and
utility data). Second, >99% of patients died, therefore,
the uncertainty in modelling future health beneﬁts is
largely absent. Third, utility data were collected until pro-
gression/death for all patients, thereby providing reliable
mean postprogression utility estimates. Moreover, the
EQ-5D utility data had good completion rates. Despite
short survival times, costs and beneﬁts were adequately
captured.
A strength of this research is the low rate of EGFR
mutation-positive tumours in our population. Currently,
NICE recommended EGFR mutation-positive locally
advanced or metastatic NSCLCs are treated with TKIs
(geﬁtinib, erlotinib or afatinib) regardless of their per-
formance status. It is possible that if ER patients were to
be compared with a similar TKI, the ICER may be higher
due to smaller differences between groups. Several other
CE analyses exist that compared TKIs against placebo
and were approved by NICE.31 It is also acknowledged
that the analysis associated with rash was not based on a
randomised comparison, so there may be some unknown
confounders. We excluded deaths prior to the ﬁrst cycle,
but there were only 32 (9%) versus 35 (11%), which was
not statistically signiﬁcant, so unlikely to impact the
results (because the survival time was <1 month in both
treatment groups, the mean OS and PFS would be very
similar). In addition, despite being statistically signiﬁcant
differences of 37% versus 24% in smoking status
(p=0.003) with median OS improvement of 2 months
(erlotinib vs placebo) for ex-smokers and 1.4 months for
current smokers, this did not translate to a meaningful
QALY difference. The mean QALY was 0.11 and 0.15
(p=0.1580) for current and ex-smokers, respectively. This
suggests that the observed differences in smoking status
did not appear to result in meaningful differences in the
ICER: about £47 000 (ex-smoker) to £64 000 (current
smoker) assuming the same incremental costs. These
values of the ICER are within the range of the sensitivity
analyses for the overall ICER.
The low EGFR mutation rate (5%) was insufﬁcient to
establish the cost-effectiveness of erlotinib for poor per-
formance patients whose tumours are EGFR mutation
+ve. In any case, the target population in this trial may
not require the (expense of) testing for EGFR mutation
status and patients could stop taking erlotinib after the
ﬁrst cycle of rash. In this trial 124/302 (40%) patients
without rash continued to receive erlotinib. With the
proposed treatment strategy, 40% of patients who took
erlotinib would fall into this category and reduce the
costs of erlotinib. Therefore, the cost saving could be
much higher. Interestingly, all patients who tested posi-
tive for EGFR mutation developed rash.
Using the ﬁndings from our trial, we estimate that of
100 patients needing to be treated with erlotinib, 60
develop treatment-related rash, who are likely to beneﬁt.
The inclusion of the ENR costs for the ﬁrst cycle
(28 days) is justiﬁed because it represents a health
resource consumed, although these patients are unlikely
to improve. The ICER was £56 770/QALY excluding the
cost of treating the 40% of non-rash patients for one
cycle, and £68 906/QALY including this cost. Both are
within the range (£30 000 to £154 000/QALY) of other
estimates for geﬁtinib and afatinib as ﬁrst-line therapy
for EGFR-mutation-positive patients with NSCLC.
Although the mean cost from 28 days of erlotinib use in
patients with ENR has been included (when calculating
the ICER of £68 906), the ICER does not reﬂect the
negative effects and poorer QoL (dis-utility) from erloti-
nib use in the patients with ENR group after ﬁrst cycle
of treatment. Therefore, the higher ICER of £68 906,
while reﬂecting total erlotinib usage, may not reﬂect the
efﬁciency of erlotinib for the target population.
In conclusion, erlotinib offers a potentially cost-
effective treatment option for the subgroup of predom-
inantly poor performance patients with NSCLC with
EGFR wild-type tumours who develop ﬁrst-cycle rash and
who are considered unﬁt by clinicians to be treated with
ﬁrst-line chemotherapy.
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